Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast In Primary Sclerosing Cholangitis To Be Highlighted In A Late-Breaking Presentation At The Liver Meeting 2024
Portfolio Pulse from Benzinga Newsdesk
Pliant Therapeutics will present Phase 2a trial results of bexotegrast for primary sclerosing cholangitis at The Liver Meeting 2024. The data shows improvement in cholestasis markers and stabilization of liver fibrosis markers.
October 17, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pliant Therapeutics will present positive Phase 2a trial results for bexotegrast in treating primary sclerosing cholangitis at The Liver Meeting 2024. This could boost investor confidence and impact stock prices positively.
The announcement of positive trial results and a presentation at a major conference can increase investor interest and confidence in Pliant Therapeutics, potentially leading to a positive impact on stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100